Skip to main content

Determining Whether Durvalumab in Combination with Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Trial Status: Active

This phase II trial studies how well durvalumab and radiation therapy work in treating patients with stage II-III non-small cell lung cancer. Immunotherapy with durvalumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab and radiation therapy may delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

Inclusion Criteria

  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations
  • Newly diagnosed or recurrent locally-advanced NSCLC (stage II – III) amenable for treatment with concurrent definitive radiation and durvalumab
  • Ineligible for resection and concurrent chemoradiation therapy (CRT) as determined by one of the following reasons: Medically inoperable, surgically unresectable (including N3 nodal disease), medically unfit or unsafe for chemotherapy, or other reason deemed appropriate by the investigator and approved by principal investigator (PI) * Note: The reason a patient is deemed ineligible for concurrent CRT must be documented (i.e. hearing impairment, neuropathy, renal dysfunction, symptomatic/advanced underlying medical comorbidities, etc.
  • Histological and/or cytological confirmation of NSCLC (both squamous and adenocarcinoma) as per standard of care biopsy; no additional research protocol-specific biopsy is needed
  • Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status (PS) 0-2
  • Candidates for definitive RT to 60 Gy in 30 fractions
  • Body weight > 30 kg
  • Hemoglobin >= 9.0 g/dL
  • Absolute neutrophil count (ANC) 1.5 x (>= 1500 per mm^3)
  • Platelet count >= 75 x 10^9/L (>= 75,000 per mm^3)
  • Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
  • Measured creatinine clearance (CL) > 15 mL/min or calculated creatinine CL > 15 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance
  • Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) * Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Must have a life expectancy of at least 12 weeks

Exclusion Criteria

  • Participation in another clinical study with an investigational product during the last 4 weeks
  • Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  • Previous thoracic radiation precluding definitive RT
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], acute diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion: * Patients with vitiligo or alopecia * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement * Any chronic skin condition that does not require systemic therapy * Patients without active disease in the last 5 years may be included but only after consultation with the study physician * Patients with celiac disease controlled by diet alone
  • Any unresolved toxicity National Cancer Institute (NCI) CTCAE grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria * Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study physician
  • Prior/Current Therapies: * Treatment with a monoclonal antibody within 4 weeks prior to study day 1 or has not recovered (i.e., >= grade 1 at baseline) from adverse events due to agents administered > 4 weeks earlier (intraocular bevacizumab is acceptable) * Prior chemotherapy or targeted small molecule therapy, within 3 weeks prior to study day 1 or has not recovered (i.e., >= grade 1 at baseline) from adverse events due to a previously administered agent (excluding grade 2 peripheral neuropathy) * Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways * Current or prior use of immunosuppressive medication within 7 days before the first dose of durvalumab. The following are exceptions to this criterion: ** Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) ** Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent ** Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication) * Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable * Prior chemotherapy for this diagnosis of lung cancer
  • Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable
  • History of allogenic organ transplantation
  • Severe concurrent illness: * Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy * Active known infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), or hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA). Testing for hepatitis C and human immunodeficiency virus (HIV) is not required unless clinically indicated. * Evidence of interstitial lung disease or active, non-infectious pneumonitis * Clinically significant (i.e., active) cardiovascular disease: Symptomatic cerebral vascular accident/stroke (< 6 months prior to enrollment) without neurological recovery, unstable angina, congestive heart failure (>= New York Heart Association Classification Class III), or serious cardiac arrhythmia uncontrolled with current medication.
  • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ a highly effective birth control from screening to 90 days after the last dose of durvalumab monotherapy. * Highly effective methods of contraception, defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly are described. Note that some contraception methods are not considered highly effective (e.g. male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action [excluding Cerazette/desogestrel which is considered highly effective]; and triphasic combined oral contraceptive pills) ** Barrier/intrauterine methods: *** Copper T intrauterine device *** Levonorgestrel-releasing intrauterine system (e.g., Mirena) **** This is also considered a hormonal method ** Hormonal methods: *** Implants: Etonogestrel-releasing implants: e.g. Implanon or Norplant *** Intravaginal: Ethinylestradiol/etonogestrel-releasing intravaginal devices: e.g. NuvaRing *** Injection: Medroxyprogesterone injection: e.g. Depo-Provera *** Combined Pill: Normal and low dose combined oral contraceptive pill *** Patch: Norelgestromin/ethinylestradiol-releasing transdermal system: e.g. Ortho Evra *** Minipillc: Progesterone based oral contraceptive pill using desogestrel: Cerazette is currently the only highly effective progesterone-based
  • Live vaccination within 4 weeks prior to the first dose of durvalumab and while on trial is prohibited except for administration of inactivated vaccines
  • Connective tissue disorders involving the lung(s) and/or esophagus requiring active treatment or idiopathic pulmonary fibrosis
  • Known actionable EGFR or ALK mutation
  • Known contraindications to radiotherapy
  • History of leptomeningeal carcinomatosis
  • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients


Miami Cancer Institute
Status: ACTIVE
Contact: Rupesh Rajesh Kotecha
Phone: 786-596-2000

New Jersey

Basking Ridge
Memorial Sloan Kettering Basking Ridge
Status: ACTIVE
Contact: Andreas Rimner
Phone: 212-639-6025
Memorial Sloan Kettering Monmouth
Status: ACTIVE
Contact: Andreas Rimner
Phone: 212-639-6025
Memorial Sloan Kettering Bergen
Status: ACTIVE
Contact: Andreas Rimner
Phone: 212-639-6025

New York

Memorial Sloan Kettering Commack
Status: ACTIVE
Contact: Andreas Rimner
Phone: 212-639-6025
New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Andreas Rimner
Phone: 212-639-6025
Memorial Sloan Kettering Nassau
Status: ACTIVE
Contact: Andreas Rimner
Phone: 212-639-6025
West Harrison
Memorial Sloan Kettering Westchester
Status: ACTIVE
Contact: Andreas Rimner
Phone: 212-639-6025


Lehigh Valley Hospital-Cedar Crest
Status: ACTIVE
Contact: Brian J. Patson
Phone: 888-402-5846


I. To demonstrate an improvement in 2-year progression-free survival (PFS) rate compared to historical results.


I. 2- year overall survival.

II. Objective response rate as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

III. Duration of response and time to distant metastases.

IV. Safety and tolerability of concurrent and adjuvant consolidation durvalumab added to thoracic radiation using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

V. Local control of NSCLC and progression free survival.


I. To elucidate early circulating tumor deoxyribonucleic acid (DNA) response.

II. Tissue and blood biomarker correlatives for response and toxicity.

III. PD-L1 expression of the primary tumor and germline testing; specifically, the investigation of HLA and germline repair deficiencies as evaluated by Memorial Sloan Kettering (MSK)-integrated mutation profiling of actionable cancer targets (IMPACT).

IV. To assess response of primary and mediastinal lymph nodes using research magnetic resonance images (MRIs) of locally advanced non-small cell lung cancer (NSCLC) patients being treated with conventionally fractionated radiation therapy.


Patients undergo radiation therapy (RT) weekly Monday-Friday over 30 fractions and also receive durvalumab intravenously (IV) over 1 hour once every 4 weeks for up to 13 cycles (1 year) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 2 years.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Andreas Rimner

  • Primary ID 19-218
  • Secondary IDs NCI-2019-05124
  • ID NCT03999710